Z Contains A Cyclopentyl Or Cyclopentene Ring Patents (Class 514/530)
-
Publication number: 20150073005Abstract: To provide a composition for hair growth (hair growth agent) which has high hair growing effects and can be used for prevention or treatment of alopecia. The composition for hair growth comprises as an active ingredient at least one member selected from the group consisting of a compound represented by the formula (1) and a salt thereof. In the formula, R is a carboxy group or an alkoxycarbonyl group.Type: ApplicationFiled: November 17, 2014Publication date: March 12, 2015Applicants: ASAHI GLASS COMPANY, LIMITED, SANTEN PHARMACEUTICAL, CO., LTD.Inventors: Atsushi Shimazaki, Arata Yasuda, Yasushi Matsumura
-
Publication number: 20150064230Abstract: The lacrimal implant delivery systems and methods described herein provide for controlled release of a therapeutic agent for the treatment of disease, including the treatment of glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agents. Treatment of disease, including glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agent in conjunction with penetration enhancer, such as benzalkonium chloride, and/or artificial tears is also provided.Type: ApplicationFiled: August 25, 2014Publication date: March 5, 2015Inventors: Zuhal Butuner, Deepank Utkhede, Sylie Sim, David J. Wiseman
-
Publication number: 20150051276Abstract: Compounds are used as agents that deter feeding of crops by agricultural pests such as hemiptera, lepidoptera and coleoptera, including, but not limited to, stink bugs, codling moth larvae and granary weevils.Type: ApplicationFiled: April 30, 2013Publication date: February 19, 2015Inventor: Robert H. Bedoukian
-
Publication number: 20150037377Abstract: The present invention relates to substituted cellulose acetates and methods of use thereof. One embodiment of the present invention provides a coating having a substituted cellulose acetate having a polar substituent that has an oxygen atom covalently bonded to a nonmetal selected from the group of sulfur, phosphorus, and boron; wherein the nonmetal is present in at least about 0.01% by weight of the substituted cellulose acetate.Type: ApplicationFiled: October 16, 2014Publication date: February 5, 2015Applicant: Celanese Acetate LLCInventors: Michael T. Combs, Thomas S. Garrett
-
Publication number: 20150025020Abstract: The present invention relates to a self-preserved oil dispersion. Especially, the present invention relates to a self-preserved oil dispersion including a dispersed oil phase, an aqueous phase and at least one surfactant, wherein said oil dispersion comprises boric acid in an amount ranging from 0.005% to 0.075% in weight of the total weight of the oil dispersion, said amount of boric acid being a preservative effective amount so that the oil dispersion has a preservative activity.Type: ApplicationFiled: February 22, 2013Publication date: January 22, 2015Inventors: Jean-Sébastien Garrigue, Frédéric Lallemand, Betty Philips
-
Publication number: 20150025077Abstract: This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.Type: ApplicationFiled: February 27, 2013Publication date: January 22, 2015Applicant: COYOTE PHARMACEUTICALS, INC.Inventors: Hiroaki Serizawa, Ankush B. Argade, Akash Datwani, Natalie Spencer, Yonghua Pan, Florian Ermini
-
Publication number: 20150018400Abstract: Disclosed herein is a method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound having a structure according to Formula I wherein X, Y, B, R2, R3, R4, R5, R6 and n have the meanings found herein.Type: ApplicationFiled: May 2, 2014Publication date: January 15, 2015Inventors: YARIV DONDE, JEREMIAH H. NGUYEN, KAREN M. KEDZIE, DANIEL W. GIL, JOHN E. DONELLO, WHA-BIN IM
-
Patent number: 8933120Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.Type: GrantFiled: December 9, 2013Date of Patent: January 13, 2015Assignee: Allergan, Inc.Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
-
Patent number: 8932567Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include bimatoprost and minoxidil in a vehicle for topical application to the skin of a mammal, e.g. a human, whereby the combination of bimatoprost and minoxidil produces a faster onset of hair growth in humans or other mammals and wherein said composition brings about a synergestic result of faster onset of hair growth as compared to compositions comprising bimatoprost and minoxidil, alone.Type: GrantFiled: January 30, 2012Date of Patent: January 13, 2015Assignee: Allergan, Inc.Inventors: David F. Woodward, Jenny W. Wang
-
Publication number: 20150005260Abstract: The present invention relates to methods and kits for detecting diastolic dysfunction in subjects without clinical signs of heart failure.Type: ApplicationFiled: January 2, 2013Publication date: January 1, 2015Inventors: Faiez Zannad, Patrick Rossignol
-
Publication number: 20150005374Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.Type: ApplicationFiled: September 18, 2014Publication date: January 1, 2015Applicant: United Therapeutics CorporationInventors: Ken Phares, David MOTTOLA, Roger Jeffs
-
Publication number: 20140371309Abstract: The present invention relates to an ophthalmic solution comprising a prostaglandin compound and viscosity-increasing compound. The ophthalmic solution of the invention is excellent in stability and can provide long lasting and increased effect when administrated topically to the eyes of a patient.Type: ApplicationFiled: August 29, 2014Publication date: December 18, 2014Applicant: SUCAMPO AGInventor: Ryuji UENO
-
Publication number: 20140371147Abstract: A combination of compounds is described for the treatment and/or prevention of skin conditions linked to hypopigmentation. Also described, is a combination product that includes at least one prostaglandin receptor agonist and at least one MC1R receptor agonist, as a medicament for use simultaneously, separately or spread out over time for the treatment and/or prevention of skin conditions linked to hypopigmentation, such as vitiligo.Type: ApplicationFiled: December 17, 2012Publication date: December 18, 2014Inventors: Philippe Martel, Itaru Suzuki, Johannes Voegel, Philippe Andres, Sandrine Rethore
-
Publication number: 20140371308Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.Type: ApplicationFiled: August 11, 2014Publication date: December 18, 2014Inventor: Patrick M. Hughes
-
Publication number: 20140371304Abstract: A method for suppressing tumorigenicity of stem cells in a mammalian subject, which comprises administering an effective amount of a fatty acid derivative and a method for suppressing tumorigenicity of stem cells of a mammalian subject, which comprises contacting said stem cell with an effective amount of a fatty acid derivative, are provided.Type: ApplicationFiled: June 11, 2014Publication date: December 18, 2014Applicant: SUCAMPO AGInventors: Ryuji UENO, Sachiko KUNO, John CUPPOLETTI
-
Publication number: 20140364400Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.Type: ApplicationFiled: August 22, 2014Publication date: December 11, 2014Inventor: Annabelle Gallois-Bernos
-
Publication number: 20140364494Abstract: Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition.Type: ApplicationFiled: August 27, 2014Publication date: December 11, 2014Inventors: Lon T. Spada, James N. Chang, Michelle H. Luu
-
Patent number: 8906907Abstract: New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward, can be easily produced, for example, using conventional manufacturing techniques, and can be easily and conveniently practiced, for example, using application or administration techniques or methodologies which are substantially similar to those employed with prior compositions used to treat ocular hypertension.Type: GrantFiled: October 24, 2013Date of Patent: December 9, 2014Assignee: Allergan, Inc.Inventors: June Chen, David F. Woodward, Alexander B. Kharlamb
-
Patent number: 8906962Abstract: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.Type: GrantFiled: September 23, 2013Date of Patent: December 9, 2014Assignee: Duke UniversityInventors: Mitchell A. deLong, John M. McIver, Robert S. Youngquist
-
Publication number: 20140350103Abstract: A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through a firsts punctum and into a first lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a second punctum and into a second lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.Type: ApplicationFiled: December 20, 2013Publication date: November 27, 2014Applicant: Mati Therapeutics, Inc.Inventors: Suzanne Cadden, Yong Hao, Deepank Utkhede, Valery Rubinchki, Charles Richard Kjellbotn
-
Publication number: 20140350104Abstract: Provided are methods of reducing body fat in a subject, comprising locally (e.g., topically) administering one or more compounds of the Formula (I) and/or (V) or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein X is —OR1 —SR2 or —NR3R4, and R1, R2, R3, R4, R5, R6, R7, R7?, Z, Y, n, y, and x, are as defined herein.Type: ApplicationFiled: December 19, 2012Publication date: November 27, 2014Applicant: Topokine Therapeutics, Inc.Inventors: Murat V. Kalayoglu, Michael S. Singer
-
Patent number: 8889735Abstract: The present invention relates to a method for treating asthenopia, accommodative dysfunction or ocular pain comprising an administration of a specific prostaglandin compound to a mammalian subject. The present invention also relates to a composition for treating asthenopia, accommodative dysfunction or ocular pain comprising a specific prostaglandin compound.Type: GrantFiled: April 6, 2012Date of Patent: November 18, 2014Assignee: Sucampo AGInventor: Ryuji Ueno
-
Publication number: 20140335056Abstract: The present invention relates to a formulation made from a chitosan, a gelatin, and a phosphate salt can provide a sustained release/maintenance of a therapeutic agent, wherein the phosphate salt is selected from the group consisting of disodium phosphate and ammonium hydrogen phosphate.Type: ApplicationFiled: May 12, 2014Publication date: November 13, 2014Inventors: Shih-Hwa CHIOU, Catherine Jui-Ling LIU, Yung-Hsin CHENG
-
Patent number: 8877807Abstract: The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions.Type: GrantFiled: February 13, 2014Date of Patent: November 4, 2014Assignee: Topokine Therapeutics, Inc.Inventors: Cynthia L. Grosskreutz, Louis R. Pasquale, Michael S. Singer, Murat V. Kalayoglu
-
Patent number: 8877732Abstract: The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit.Type: GrantFiled: January 11, 2011Date of Patent: November 4, 2014Assignee: Inotek Pharmaceuticals CorporationInventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley, Rudolf A. Baumgartner
-
Publication number: 20140323561Abstract: Control and repellency of biting flies, house flies, ticks, ants, fleas, biting midges, cockroaches, spiders and stink bugs is obtained by contact of the insects with at least one of the compounds of the structure (I).Type: ApplicationFiled: October 21, 2013Publication date: October 30, 2014Inventor: Robert H. Bedoukian
-
Publication number: 20140322148Abstract: Described herein are topical oil-based formulations that find use in the treatment of alopecia, i.e., hair loss, and in the promotion of hair growth.Type: ApplicationFiled: November 20, 2012Publication date: October 30, 2014Inventor: Adrianna Janell JACKSON
-
Publication number: 20140314868Abstract: Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma.Type: ApplicationFiled: July 3, 2014Publication date: October 23, 2014Inventors: Michael R. Robinson, Hui Liu, Patrick M. Hughes, Lon T. Spada, Alazar N. Ghebremeskel
-
Patent number: 8865685Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.Type: GrantFiled: June 13, 2012Date of Patent: October 21, 2014Assignee: Johnson & Johnson Vision Care, Inc.Inventor: Annabelle Gallois-Bernos
-
SUSTAINED RELEASE BIMATOPROST, BIMATOPROST ANALOGS, PROSTAMIDES AND PROSTAGLANDINS FOR FAT REDUCTION
Publication number: 20140308354Abstract: The present invention is directed to compositions and methods for injection into fat deposits for sustained release of compounds which result in localized fat reduction.Type: ApplicationFiled: April 9, 2014Publication date: October 16, 2014Applicant: ALLERGAN, INC.Inventors: SCOTT WHITCUP, DAVID WOODWARD, PATRICK HUGHES -
Publication number: 20140303166Abstract: The current application is directed to cosmetic methods for changing the appearance of eyes by causing a retraction of the eyelids so that the eyes appear to be more open and have a wider appearance. Various methods involve application of one or more prostaglandins, synthetic prostaglandins, including synthetic prostaglandin F, and synthetic prostaglandin analogues, to eyelids, which results in contraction of eyelid muscles and a wider, more open appearance of the eyes.Type: ApplicationFiled: April 8, 2013Publication date: October 9, 2014Inventor: Gordon C. Tang
-
Patent number: 8853268Abstract: The present invention relates to an ophthalmic solution comprising a prostaglandin compound and viscosity-increasing compound. The ophthalmic solution of the invention is excellent in stability and can provide long lasting and increased effect when administrated topically to the eyes of a patient.Type: GrantFiled: October 8, 2013Date of Patent: October 7, 2014Assignee: Sucampo AGInventor: Ryuji Ueno
-
Publication number: 20140294750Abstract: The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include at two different polyols in conjunction with borate, a preservative or both.Type: ApplicationFiled: June 13, 2014Publication date: October 2, 2014Inventors: Bhagwati P. Kabra, Rajni Jani
-
Patent number: 8829018Abstract: The present invention relates to methods of treating metabolic syndrome, Type 2 diabetes mellitus, atherogenic dyslipidemia and/or obesity. The present invention also relates to methods of restoring the incretin effect, to restoring physiologic control of glucagon levels, to restoring first-phase insulin secretion, and to restoring the physiologic glucose-dependent insulin secretion. The methods of the present invention comprise administration of a selective ?-receptor antagonist, such as guanidinylated naltrindole (GNTI), or pharmaceutically acceptable derivatives thereof to a subject in need thereof.Type: GrantFiled: April 10, 2013Date of Patent: September 9, 2014Assignee: Neurendo Pharma, LLCInventor: Anton H. Clemens
-
Patent number: 8822507Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”).Type: GrantFiled: May 3, 2013Date of Patent: September 2, 2014Assignee: PIMCO 2664 LimitedInventors: Iain Robert Greig, Rose Mary Sheridan, Raymond Fisher, Matthew John Tozer, Juha Andrew Clase, Andrew Smith, Andrew Robert Tuffnell, Robert Jurgen Van 't Hof
-
Publication number: 20140243409Abstract: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.Type: ApplicationFiled: May 1, 2014Publication date: August 28, 2014Applicant: Alcon Research, Ltd.Inventor: Bhagwati P. Kabra
-
Publication number: 20140235665Abstract: An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in a ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I): where X1 and X2 are preferably both fluorine atoms. The composition can be used to treat constipation without substantive side-effects, such as stomachache.Type: ApplicationFiled: April 30, 2014Publication date: August 21, 2014Applicant: SUCAMPO AGInventor: Ryuji UENO
-
Publication number: 20140228364Abstract: The present invention relates to a composition comprising at least one analogue of prostaglandin as active compound, and a stabilizing amount of at least one hyaluronic acid or a salt thereof, said composition being preservative-free; and to the use thereof for use in treating ocular hypertension and/or glaucoma in a subject in need thereof.Type: ApplicationFiled: September 11, 2012Publication date: August 14, 2014Inventor: Reda Hadj-Slimane
-
Patent number: 8802680Abstract: Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: ?12-prostaglandin J3 or a derivative thereof, or a prostaglandin D receptor (DP) agonist. The compositions may further include a second anti-cancer drug. ?12-prostaglandin J3 is a stable metabolite of omega-3 fatty acid, eicosapentaenoic acid (EPA), and was discovered to have anti-leukemic properties. ?12-prostaglandin J3 was shown to be highly effective in eradicating the leukemia stem cells (LSC) in two murine models of leukemia, thus increasing the survival of the mice. DP agonists were shown to induce apoptosis of human primary Acute Myelogenous Leukemia cells and may be used in compositions, kits and methods for treating leukemia in a subject. The compositions, kits and methods may be particularly useful for treating human subjects who are resistant to one or more anti-cancer drugs.Type: GrantFiled: June 29, 2012Date of Patent: August 12, 2014Assignee: The Penn State Research FoundationInventors: Kumble Sandeep Prabhu, Robert Frank Paulson, Shailaja Hegde, Naveen Kaushal, Ujjawal Hitendra Gandhi
-
Publication number: 20140220132Abstract: The current invention pertains to pharmaceutical formulation including at least one jasmonate compound of the jasmonate family of compounds combined with a carrier, such as inclusion compounds, particularly those able to form nano or micro encapsulation systems. The invention generally refers to inclusion complexes which includes jasmonate compounds.Type: ApplicationFiled: February 27, 2012Publication date: August 7, 2014Inventor: José E. Fehr Pereira Lopes
-
Publication number: 20140213646Abstract: The present embodiments provide for methods of treating elevated intraocular pressure or glaucoma using a sustained release medicament consisting of prostaglandin in benzyl benzoate that is injected intraocularly no more frequently than once every two months.Type: ApplicationFiled: January 30, 2014Publication date: July 31, 2014Inventors: Vernon G. Wong, Mae W. Hu, Glenn T. Huang
-
Patent number: 8791159Abstract: A compound having an ability to bind to an SIP receptor and represented by formula (I), a salt thereof, a solvate thereof or a prodrug thereof is useful for prevention and/or treatment of rejection of transplantation, graft-versus-host disease, autoimmune disease, allergic disease and the like: wherein ring A is a cyclic group; ring B is a cyclic group which may have substituent(s); X is a spacer having 1 to 8 atoms in its main chain, etc.; Y is a spacer having 1 to 10 atoms in its main chain, etc.; n is 0 or 1, wherein when n is 0, m is 1 and R1 is a hydrogen atom or a substituent, and wherein when n is 1, m is 0 or an integer of 1 to 7 and R1 is a substituent, and wherein m is 2 or more, R1s are the same or different.Type: GrantFiled: September 10, 2010Date of Patent: July 29, 2014Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Shinji Nakade, Hirotaka Mizuno, Takeji Ono, Masashi Minami, Hiroshi Saga, Hiroshi Hagiya, Takaki Komiya, Hiromu Habashita, Haruto Kurata, Kazuhiro Ohtsuki, Kensuke Kusumi
-
Publication number: 20140205649Abstract: The present invention provides a sustained release latanoprost implant in the form of a thin film comprising latanoprost incorporated in a biodegradable polymer matrix. Preferably, said implant is an intraocular implant comprising a thin film comprising latanoprost incorporated in a biodegradable polymer matrix wherein said implant is configured as a disc or a rolled film that can be inserted into the eye and unrolls to provide a film having a high surface area to volume ratio.Type: ApplicationFiled: March 20, 2014Publication date: July 24, 2014Applicant: ALLERGAN, INC.Inventors: Alazar N. Ghebremeskel, Lon T. Spada
-
Patent number: 8785494Abstract: The invention relates to novel calcium-sensing receptor (CaSR) modulating trifluoromethylphenylene cyclopentylene compounds represented in formula (I) and derivatives thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.Type: GrantFiled: May 26, 2010Date of Patent: July 22, 2014Assignee: LEO-Pharma A/SInventor: Bjarne Nørremark
-
Publication number: 20140194497Abstract: Provided is a composition for scalp and hair treatment, including a menthol derivative and a prostaglandin compound having two hetero atoms at the 15 position. The composition of the present invention is effective not only for preventing dandruff and itchy scalp but also for preventing or treating hair loss, baldness, or hair thinness.Type: ApplicationFiled: February 6, 2014Publication date: July 10, 2014Applicant: R-TECH Ueno, Ltd.Inventors: Masato IINO, Satoshi YAMAKI, Satoshi NAKANISHI, Masahiro TAJIMA, Ryuji UENO
-
Patent number: 8772338Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.Type: GrantFiled: March 14, 2013Date of Patent: July 8, 2014Assignee: Allergan, Inc.Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
-
Patent number: 8772337Abstract: The present invention provides an ophthalmic solution without an antimicrobial preservative. The solution includes as an active substance at least one prostaglandin and as a solubilizing agent, a surfactant, where the solubilizing agent is polyoxyl-15-hydroxystearate.Type: GrantFiled: July 17, 2008Date of Patent: July 8, 2014Assignee: Laboratoires TheaInventors: Frederic Pilotaz, Fabrice Mercier, Henri Chibret
-
Publication number: 20140186420Abstract: A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.Type: ApplicationFiled: December 5, 2013Publication date: July 3, 2014Applicant: Mati Therapeutics, Inc.Inventors: Deepank Utkhede, Robert W. Shimizu, Rachna Jain, Stephen Boyd, Hanson S. Gifford, Eugene De Juan, JR., Cary J. Reich
-
Publication number: 20140187617Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.Type: ApplicationFiled: December 23, 2013Publication date: July 3, 2014Applicant: AERIE PHARMACEUTICALS, INC.Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
-
Publication number: 20140187497Abstract: A method of forming an ocular delivery device includes exposing a solid, shaped cellulose polymer to a solution including an active pharmaceutical ingredient (API) and a solvent capable of solubilizing the API, wherein the polymer absorbs at least a portion of the solution, including the API and solvent. The method may further include removing at least a portion of the absorbed solvent from the polymer by allowing the absorbed solvent to evaporate from the polymer or by drying the polymer. A variety of cellulose polymers may be used, including hydroxypropyl cellulose. A variety of APIs may be used, including Cyclosporine, Tobramycin and Vancomycin. Ocular delivery devices prepared by the methods may be used to treat a variety of eye disorders.Type: ApplicationFiled: November 22, 2013Publication date: July 3, 2014Applicants: Louisiana State University Agricultural and Mechanical College, ATON PHARMA, INC.Inventors: Jean Theresa JACOB, Kevin John HALLORAN, Yuri MCKEE